Exelixis
EXEL
#1725
Rank
S$12.88 B
Marketcap
$45.11
Share price
-1.16%
Change (1 day)
44.84%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : S$3.08 Billion

According to Exelixis's latest financial reports the company has S$3.08 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$S$2.98 B-10.37%
2022-12-31$S$3.33 B11.63%
2021-12-31$S$2.98 B20.22%
2020-12-31$S$2.48 B9.37%
2019-12-31$S$2.27 B29.23%
2018-12-31$S$1.75 B361.48%
2017-12-31$S$0.38 B194.84%
2016-12-31$S$0.12 B-164.9%
2015-12-31$-S$0.2 Billion31.27%
2014-12-31$-S$0.16 Billion-280.8%
2013-12-31$S$83.92 M-76.85%
2012-12-31$S$0.36 B208.85%
2011-12-31$S$0.11 B-139.91%
2010-12-31$-S$0.3 Billion27.96%
2009-12-31$-S$0.23 Billion185.68%
2008-12-31$-S$80.46 Million-165.39%
2007-12-31$S$0.12 B-11.44%
2006-12-31$S$0.13 B45.65%
2005-12-31$S$95.39 M15.4%
2004-12-31$S$82.66 M-69.87%
2003-12-31$S$0.27 B-10.12%
2002-12-31$S$0.30 B-30.49%
2001-12-31$S$0.43 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
S$24.39 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
S$106.03 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
S$60.38 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
S$23.30 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
S$10.19 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
S$95.07 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
S$125.42 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$11.84 Million-100.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$39.08 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA